<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html dir="ltr" xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml">
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>

<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<!-- 
	This website is powered by TYPO3 - inspiring people to share!
	TYPO3 is a free open source Content Management Framework initially created by Kasper Skaarhoj and licensed under GNU/GPL.
	TYPO3 is copyright 1998-2015 of Kasper Skaarhoj. Extensions are copyright of their respective owners.
	Information and contribution at http://typo3.org/
-->



<title>INHN: Bulletin 71 : Update (Volume Nine): 3a. Interviewee’s Contributions</title>
<meta name="generator" content="TYPO3 4.5 CMS" />

<link rel="stylesheet" type="text/css" href="IMAGES/STYLESHEET_9B1E31873F2366.CSS?1645000983" media="all" />



<script src="IMAGES/JAVASCRIPT_93077BB238F3E1.JS?1645000982" type="text/javascript"></script>


<link href="IMAGES/LAYOUT_3COL_STANDARD.CSS" rel="stylesheet" type="text/css" /><!--[if lte IE 7]><link href="fileadmin/styles/patches/../01_layouts_basics/css/patches/patch_3col_standard.css" rel="stylesheet" type="text/css" /><![endif]-->
<meta name="DC.title" content="Bulletin 71 : Update (Volume Nine): 3a. Interviewee’s Contributions" />
<meta name="description" content="INHN" />
<meta name="DC.Description" content="INHN" />
<meta name="keywords" content="International Network for the History of Neuropsychopharmacology" />
<meta name="DC.Subject" content="International Network for the History of Neuropsychopharmacology" />
<meta name="copyright" content="Copyright INHN 2012-14" />
<meta name="DC.Rights" content="Copyright INHN 2012-14" />
<meta http-equiv="content-language" content="en" />
<meta name="DC.Language" scheme="NISOZ39.50" content="en" />
<link rev="made" href="mailto:inhn@inhn.org" />
<meta http-equiv="reply-to" content="inhn@inhn.org" />
<meta name="author" content="Gregers Wegener" />
<meta name="DC.Creator" content="Gregers Wegener" />
<meta name="rating" content="General" />
<meta name="date" content="2019-04-30T20:52:42+00:00" />
<meta name="DC.date" content="2019-04-30T20:52:42+00:00" />
<meta name="robots" content="index,follow" />
<meta name="revisit-after" content="7" />
<link rel="start" href="INDEX681A.HTM?id=1" />
<link rel="up" href="INDEX768D.HTM?id=2359" />
<link rel="next" href="INDEX48C2.HTM?id=3021" />
<link rel="prev" href="INDEXBD8C.HTM?id=2988" />
<link rel="canonical" href="INDEX2A75.HTM?id=3004" />



</head>
<body id="pageUID-3004">


<div id="page_margins">
	<div id="page">
		<div id="header"><div class="tx-macinasearchbox-pi1">
		
<form action="https://inhn.org/index.php?id=5&amp;L=0" method="post" name="searchform" id="searchform">
<input name="tx_indexedsearch[sword]" type="text" value="Enter search word..." onclick="this.value=''" onblur="this.value='Enter search word...'" /><br />
<input type="hidden" name="tx_indexedsearch[_sections]" value="0" />
<input type="hidden" name="tx_indexedsearch[pointer]" value="0" />
<input type="hidden" name="tx_indexedsearch[ext]" value="0" />
<input type="hidden" name="tx_indexedsearch[lang]" value="0" />
</form>

	</div>
	<div id="topnav"><a class="skip" href="#navigation" title="Direkt zur Navigation springen">Zur Navigation springen</a><span class="hideme">.</span><a class="skip" href="#content" title="Direkt zum Content springen">Zum Content springen</a><span class="hideme">.</span><a href="INDEX3A9F.HTM?id=6" target="_self">Sitemap</a>&nbsp;&#124;&nbsp;<a href="INDEXD61C.HTM?id=5" target="_self">Search</a>&nbsp;&#124;&nbsp;<a href="INDEX65E4.HTM?id=kontakt" target="_self">Contact</a>&nbsp;&#124;&nbsp;<a href="INDEXB7B8.HTM?id=204" target="_self">About INHN</a></div><a href="INDEX2999.HTM?id=202"><img class="headImg1" src="IMAGES/COMPANY_LOGO.GIF" alt="" title="Home" width="598" height="100" /></a></div>
		<div id="nav"><a id="navigation" name="navigation"></a><div id="nav_main" class="hlist"><ul><li id="current"><a href="INDEX2999.HTM?id=202" target="_self"><span>Home</span></a></li><li><a href="INDEX7EFD.HTM?id=479" target="_self"><span>Dictionary</span></a></li><li><a href="INDEX3E5C.HTM?id=374" target="_self"><span>Drugs</span></a></li><li><a href="INDEXDBB1.HTM?id=565" target="_self"><span>Photos</span></a></li><li><a href="INDEXD919.HTM?id=342" target="_self"><span>Profiles</span></a></li><li><a href="INDEXAF9F.HTM?id=355" target="_self"><span>Controversies</span></a></li><li><a href="INDEXD122.HTM?id=641" target="_self"><span>Discoveries</span></a></li><li><a href="INDEX1F24.HTM?id=384" target="_self"><span>Books</span></a></li><li><a href="INDEX3958.HTM?id=467" target="_self"><span>Biographies</span></a></li><li><a href="INDEX677F.HTM?id=642" target="_self"><span>Perspectives</span></a></li><li><a href="INDEX8C00.HTM?id=343" target="_self"><span>Archives</span></a></li><li><a href="INDEX06CB.HTM?id=368" target="_self"><span>Ebooks</span></a></li><li><a href="INDEXA1F1.HTM?id=1755" target="_self"><span>Collated</span></a></li><li><a href="INDEXDF25.HTM?id=4128" target="_self"><span>Multilingual Project</span></a></li><li><a href="INDEXABE4.HTM?id=3884" target="_self"><span>INHN Publisher</span></a></li></ul></div></div>
		<div id="main">
			<div id="teaser" class="clearfix"><div class="rootline">You are here: <a href="INDEX2999.HTM?id=202" target="_self">Home</a>&nbsp;/&nbsp;<a href="INDEX3F39.HTM?id=1016" target="_self">Central Office (Cordoba Unit)</a>&nbsp;/&nbsp;<a href="INDEXC279.HTM?id=1659" target="_self">EDUCATION</a>&nbsp;/&nbsp;<a href="INDEX768D.HTM?id=2359" target="_self">Thomas A. Ban Neuropsychopharmacology in Historical Perspective - Education in the Field in the Post-Neuropsychopharmacology Era</a>&nbsp;/&nbsp;Bulletin 71 : Update (Volume Nine): 3a. Interviewee’s Contributions</div><div class="langMenu"><div class="tx-srlanguagemenu-pi1">
		
	</div>
	</div></div>
			<div id="col1">
				<div id="col1_content" class="clearfix">
					<ul id="submenu"><li id="title">Home</li><li><a href="INDEXB7B8.HTM?id=204" target="_self">About INHN</a><span class="hidden">.</span></li><li><a href="INDEXC104.HTM?id=854" target="_self">Towards education</a><span class="hidden">.</span></li><li><a href="INDEX3F39.HTM?id=1016" target="_self">Central Office (Cordoba Unit)</a><span class="hidden">.</span><ul><li><a href="INDEXEC89.HTM?id=1265" target="_self">Carlos Morra: Central Office</a></li><li><a href="INDEXF6AE.HTM?id=1234" target="_self">Administrative Unit by Leon S. Morra</a></li><li><a href="INDEXA81B.HTM?id=1233" target="_self">Carlos Morra: Chronological list of essential publications</a></li><li><a href="INDEXFC5C.HTM?id=3915" target="_self">Carlos Morra: Guide for Authors</a></li><li><a href="INDEX7A09.HTM?id=1123" target="_self">Thomas A. Ban: Recommended additions</a></li><li><a href="INDEX15CB.HTM?id=1587" target="_self">ADMINISTRATIVE UNIT</a><span class="hidden">.</span></li><li><a href="INDEXC279.HTM?id=1659" target="_self">EDUCATION</a><span class="hidden">.</span><ul><li><a href="INDEX768D.HTM?id=2359" target="_self">Thomas A. Ban Neuropsychopharmacology in Historical Perspective - Education in the Field in the Post-Neuropsychopharmacology Era</a><span class="hidden">.</span><ul><li><a href="INDEX114E.HTM?id=2360" target="_self">Bulletin 1: Educational Series 2. Jacques-Joseph Moreau de Tours.</a></li><li><a href="INDEX9E33.HTM?id=2367" target="_self">Bulletin 2 : Educational Series 2.Prologue</a></li><li><a href="INDEX1338.HTM?id=2375" target="_self">Bulletin 3 : Educational Series 2.  Vignette 1 Overview of the series: An Oral History of Neuropsychopharmacology</a></li><li><a href="INDEXF2B4.HTM?id=2385" target="_self">Bulletin 4 : Educational Series 2. Chapter 1: John Dalton’s atomic theory and drugs in psychiatry in the 19th century</a></li><li><a href="INDEXAEB2.HTM?id=2388" target="_self">Educational Series 2. Bulletin 5. Vignette 2: Sedatives in the second part of the 19th century</a></li><li><a href="INDEX8D36.HTM?id=2399" target="_self">Educational Series 2. Bulletin 6, Chapter 2: From William Cullen’s “neuroses” to Johann Christian Reil’s “psychiaterie”</a></li><li><a href="INDEX05B0.HTM?id=2404" target="_self">Educational Series 2. Bulletin 7, Vignette 3: Classifications of insanity in the late 18th and early 19th century</a></li><li><a href="INDEX525B.HTM?id=2414" target="_self">Educational Series 2. Bulletin 8, Chapter 3: Substances with an effect on consciousness</a></li><li><a href="INDEXA355.HTM?id=2422" target="_self">Educational Series 2. Bulletin 9 Vignette 4 :The isolation of morphine</a></li><li><a href="INDEX3BEE.HTM?id=2431" target="_self">Bulletin 10 : Reflexes of the brain</a></li><li><a href="INDEX8D24_2.HTM?id=2438" target="_self">Bulletin 11 : Sechenov’s re-evaluation of mental faculties and the brain</a></li><li><a href="INDEX796C.HTM?id=2451" target="_self">Bulletin 12 : Bayle’s discovery and the re-evaluation of the concept of dementia</a></li><li><a href="INDEX76A9_2.HTM?id=2458" target="_self">Bulletin 13 : Louis Sokoloff Autobiography – Regional mapping and imaging of the nervous system</a></li><li><a href="INDEXD4A9_2.HTM?id=2463" target="_self">Bulletin 14 : Joseph J. Schildkraut: Autobiography – The catecholamine hypothesis before and thereafter</a></li><li><a href="INDEXD5AC.HTM?id=2474" target="_self">Bulletin 15 : Alfred Pletscher Autobiography – On the Eve of the Birth of the Neurotransmitter Era in Biological Psychiatry</a></li><li><a href="INDEX6102.HTM?id=2483" target="_self">Bulletin 16 : Leo E. Hollister’s Interview of Julius Axelrod – The Uptake of Neurotransmitters and Psychoactive Drugs</a></li><li><a href="INDEXD4EC.HTM?id=2491" target="_self">Bulletin 17 : Thomas A. Ban’s Interview of Irwin J. Kopin – Metabolic disposition of catecholamines</a></li><li><a href="INDEXD604.HTM?id=2506" target="_self">Bulletin 18 : Thomas A. Ban’s Interview of Philip B. Bradley – Recording Electrical Activity from Cerebral Cortex and Subcortical Structures in Conscious Cats</a></li><li><a href="INDEXCD11.HTM?id=2521" target="_self">Bulletin 19 : From Conditioning and Psychiatry to Psychopharmacology*</a></li><li><a href="INDEX036F.HTM?id=2524" target="_self">Bulletin 20 : Conditioning and Psychiatry</a></li><li><a href="INDEXA67B.HTM?id=2533" target="_self">Bulletin 21 : Psychopharmacology</a></li><li><a href="INDEXA9EE_2.HTM?id=2543" target="_self">Bulletin 22 : Physiological patterns: A diagnostic test procedure based on the conditional reflex method</a></li><li><a href="INDEX8191.HTM?id=2551" target="_self">Bulletin 23 : Clinical pharmacology of psychotropic drugs</a></li><li><a href="INDEX0FE8.HTM?id=2562" target="_self">Bulletin 24 : Methodology and pitfalls in clinical testing of psychopharmacological drugs</a></li><li><a href="INDEX840B.HTM?id=2570" target="_self">Bulletin 25 : Toxicity and Adverse Reaction Studies with Neuroleptics and Antidepressants</a></li><li><a href="INDEX739E.HTM?id=2578" target="_self">Bulletin 26 : The effect of phenothiazines on the electrocardiogram</a></li><li><a href="INDEXF797.HTM?id=2586" target="_self">Bulletin 27 : Skin pigmentation, a rare side effect of chlorpromazine</a></li><li><a href="INDEX825E.HTM?id=2594" target="_self">Bulletin 28 : Ernst Feuchtersleben’s separation of psychosis from neurosis</a></li><li><a href="INDEXDC51.HTM?id=2603" target="_self">Bulletin 29 : Wilhelm Griesinger and Unitary Psychosis (Einheitpsychose)</a></li><li><a href="INDEX0C60.HTM?id=2612" target="_self">Bulletin 30 : Towards Neuropsychopharmacology in 1957</a></li><li><a href="INDEX76BD.HTM?id=2621" target="_self">Bulletin 31 : Fifty years CINP</a></li><li><a href="INDEX2103.HTM?id=2630" target="_self">Bulletin 32 : Fifty years ACNP</a></li><li><a href="INDEX6B55.HTM?id=2638" target="_self">Bulletin 33 : Starting Up (Volume One): 1. The Interviews</a></li><li><a href="INDEXEDEF.HTM?id=2647" target="_self">Bulletin 34 : Starting Up (Volume One): 2. Psychiatry</a></li><li><a href="INDEX22AE.HTM?id=2656" target="_self">Bulletin 35 : Starting Up (Volume One): 3. Drugs</a></li><li><a href="INDEXC051.HTM?id=2665" target="_self">Bulletin 36 : Starting Up (Volume One): 4. Pharmacology</a></li><li><a href="INDEX3552.HTM?id=2674" target="_self">Bulletin 37 : Starting Up (Volume One):  5. Interviewees</a></li><li><a href="INDEXBF4E.HTM?id=2683" target="_self">Bulletin 38 : Neurophysiology (Volume Two): 1. Early Development</a></li><li><a href="INDEXF887.HTM?id=2692" target="_self">Bulletin 39 : Neurophysiology (Volume Two): 2. Interviewees Contributions</a></li><li><a href="INDEX7741.HTM?id=2700" target="_self">Bulletin 40 : Neuropharmacology (Volume Three): 1. Neurotransmitters</a></li><li><a href="INDEXC58E.HTM?id=2708" target="_self">Bulletin 41 : Neuropharmacology (Volume Three): 2. Psychotropic drugs</a></li><li><a href="INDEX917B.HTM?id=2717" target="_self">Bulletin 42 : Neuropharmacology (Volume Three): 3a. Contributions of Interviewees</a></li><li><a href="INDEXBBC9.HTM?id=2726" target="_self">Bulletin 43 : Neuropharmacology (Volume Three): 3b. Contributions of Interviewees</a></li><li><a href="INDEX5AFC.HTM?id=2734" target="_self">Bulletin 44 : Psychopharmacology (Volume Four): 1. Clinical methodology</a></li><li><a href="INDEX5441.HTM?id=2751" target="_self">Bulletin 45 : Psychopharmacology (Volume Four): 2a. Contributions of Interviewees</a></li><li><a href="INDEXBB17.HTM?id=2760" target="_self">Bulletin 46 : Psychopharmacology (Volume Four): 2b. Contributions of Interviewees</a></li><li><a href="INDEX9F22.HTM?id=2761" target="_self">Bulletin 47 : Psychopharmacology (Volume Four): 2c. Contributions of Interviewees</a></li><li><a href="INDEXEFAA.HTM?id=2770" target="_self">Bulletin 48 : Neuropsychopharmacology (Volume Five): 1.Model Psychosis</a></li><li><a href="INDEX0571.HTM?id=2778" target="_self">Bulletin 49 : Neuropsychopharmacology (Volume Five): 2. Psychotoxic metabolites</a></li><li><a href="INDEX5740.HTM?id=2787" target="_self">Bulletin 50 : Neuropsychopharmacology (Volume Five): 3. Psychopharmacology of Schizophrenia; Psychopharmacology of Depression; Endocrine Measures</a></li><li><a href="INDEX47D5.HTM?id=2795" target="_self">Bulletin 51 : Neuropsychopharmacology (Volume Five): 4a. Contributions of Interviewees</a></li><li><a href="INDEXEE5A_2.HTM?id=2801" target="_self">Bulletin 52 : Neuropsychopharmacology (Volume Five): 4b. Contributions of Interviewees</a></li><li><a href="INDEX59FE.HTM?id=2810" target="_self">Bulletin 53 : Neuropsychopharmacology (Volume Five): 4c. Contributions of Interviewees</a></li><li><a href="INDEX0E71.HTM?id=2820" target="_self">Bulletin 54 : Addiction (Volume Six): 1. Addiction Psychiatry</a></li><li><a href="INDEXAE91.HTM?id=2829" target="_self">Bulletin 55 : Addiction (Volume Six): 2. Substances of abuse</a></li><li><a href="INDEX9B7D.HTM?id=2837" target="_self">Bulletin 56 : Addiction (Volume Six): 3. Conditioning and addiction</a></li><li><a href="INDEX0047_2.HTM?id=2846" target="_self">Bulletin 57 : Addiction (Volume Six): 4a. Contributions of interviewees</a></li><li><a href="INDEX44BA.HTM?id=2854" target="_self">Bulletin 58 : Addiction (Volume Six): 4b. Contributions of interviewees.</a></li><li><a href="INDEX0F23.HTM?id=2863" target="_self">Bulletin 59 : Special Areas (Volume Seven): 1. Child Psychiatry</a></li><li><a href="INDEXAA86.HTM?id=2871" target="_self">Bulletin 60 : Special Areas (Volume Seven): 2. Geriatric Psychiatry</a></li><li><a href="INDEX9ECC.HTM?id=2883" target="_self">Bulletin 61 : Special Areas (Volume Seven): 3. Psychiatric diagnosis</a></li><li><a href="INDEX1EC3.HTM?id=2892" target="_self">Bulletin 62 : Special Areas (Volume Seven): 4. Pharmacokinetics</a></li><li><a href="INDEXBAEC.HTM?id=2902" target="_self">Bulletin 63 : Special Areas (Volume Seven): 5a. Contributions of Interviewees.</a></li><li><a href="INDEX38B7.HTM?id=2921" target="_self">Bulletin 64 : Special Areas (Volume Seven): 5b. Contributions of Interviewees</a></li><li><a href="INDEX54DB.HTM?id=2938" target="_self">Bulletin 65 : Special Areas (Volume Seven): 5c. Contributions of Interviewees</a></li><li><a href="INDEX5194.HTM?id=2952" target="_self">Bulletin 66 : Diverse Topics (Volume Eight): 1. Regulation, Ethics, Marketing and Education, Conflict of Interest</a></li><li><a href="INDEXF272.HTM?id=2960" target="_self">Bulletin 67 : Diverse Topics (Volume Eight): 2a. Interviewees Contributions</a></li><li><a href="INDEXCAF4.HTM?id=2969" target="_self">Bulletin 68 : Diverse Topics (Volume Eight): 2b. Interviewees Contributions</a></li><li><a href="INDEX8272.HTM?id=2979" target="_self">Bulletin 69 : Update (Volume Nine): 1. Pharmacogenetics and Genetics and Neuropsychopharmacology</a></li><li><a href="INDEXBD8C.HTM?id=2988" target="_self">Bulletin 70 : Update (Volume Nine): 2. Psychopathology and Nosology</a></li><li><strong>Bulletin 71 : Update (Volume Nine): 3a. Interviewee’s Contributions</strong></li><li><a href="INDEX48C2.HTM?id=3021" target="_self">Bulletin 72 : Update (Volume 9) 3b. Interviewees contributions</a></li><li><a href="INDEX616E.HTM?id=3030" target="_self">Bulletin 73 : Volume 10. Postscript</a></li><li><a href="INDEX1D4A.HTM?id=3036" target="_self">Bulletin 74 : An Overview of Developments in Psychopharmacology and Neuropsychopharmacology</a></li><li><a href="INDEX2F0A.HTM?id=3048" target="_self">Bulletin 75 : The confounding of education with marketing</a></li><li><a href="INDEX1E85.HTM?id=3055" target="_self">Bulletin 76 : Towards a genetic era in neuropsychopharmacology</a></li><li><a href="INDEX5072.HTM?id=3062" target="_self">Bulletin 77 : The CODE System</a></li><li><a href="INDEXBB3A.HTM?id=3071" target="_self">Bulletin 78 : Nosologic Homotyping</a></li><li><a href="INDEX5262.HTM?id=3085" target="_self">Collated Bulletin 1: RDoC in Historical Perspective.</a></li><li><a href="INDEX8197.HTM?id=3094" target="_self">Collated Bulletin 2 : Neuropsychopharmacology and the Forgotten Language of Psychiatry</a></li><li><a href="INDEXCB60.HTM?id=3103" target="_self">Collated Bulletin 3 : In Historical Perspective: Peralta, Cuesta and their associate’s findings on the highest familiality of Leonhard’s Classification in Polynosologic Study</a></li><li><a href="INDEX55BE.HTM?id=3111" target="_self">Collated Bulletin 4: Thomas A. Ban: The Birth of a Medical Discipline: Psychiatry</a></li><li><a href="INDEX1328.HTM?id=3124" target="_self">Collated Bulletin 5: Thomas A. Ban: Conflict of Interest in Neuropsychopharmacology. Marketing vs. Education.</a></li><li><a href="INDEX9A64.HTM?id=3130" target="_self">Collated Bulletin 6: Edward Shorter: The QT interval and the Mellaril story</a></li><li><a href="INDEXC9E3.HTM?id=3143" target="_self">Collated Bulletin 7 : Thomas A. Ban: The Wernicke – Kleist – Leonhard Tradition with Special Reference to Mania, Melancholia and Manic – Depressive Psychosis</a><span class="hidden">.</span></li><li><a href="INDEX1124.HTM?id=3152" target="_self">Collated Bulletin 8 : Thomas A. Ban: The Birth of Drug Industry and Drugs with An Effect On Behavior</a></li><li><a href="INDEX1A41.HTM?id=3164" target="_self">Collated Bulletin 9 : Thomas A. Ban: From Melancholia to Depression</a></li><li><a href="INDEX4A53.HTM?id=3170" target="_self">Collated Bulletin 10 : Thomas A. Ban: The Year 1845</a></li><li><a href="INDEX4878.HTM?id=3182" target="_self">Collated Bulletin 11 : Joseph Knoll: The discovery of monoamine oxidase (MAO) enzymes</a><span class="hidden">.</span></li><li><a href="INDEX13FE.HTM?id=3200" target="_self">Collated Bulletin 12 : Samuel Gershon: Events and Memories</a></li><li><a href="INDEXBAD0.HTM?id=3287" target="_self">Collated Bulletin 13 : Paul Devenyi: Addictions are not treatable diseases and Pharmacotherapy of addiction not a success story.</a></li><li><a href="INDEX80F0.HTM?id=3297" target="_self">Collated Bulletin 14 : Janos Radó: The use of modern antidiuretic agents in the treatment of permanent lithium-induced nephrogenic diabetes insipidus</a></li><li><a href="INDEX7FB2.HTM?id=3305" target="_self">Collated Bulletin 15 : Per Bech:  Clinical Psychometrics</a></li><li><a href="INDEX2912.HTM?id=3312" target="_self">Collated Bulletin 16 : Martin M. Katz: Onset of clinical effects of antidepressants</a></li><li><a href="INDEX412B.HTM?id=3321" target="_self">Collated Bulletin 17 : Martin M. Katz: Depression and Drugs, a monograph  and Multivantaged vs Conventional Assessment, an essay</a></li><li><a href="INDEXB116.HTM?id=3330" target="_self">Collated Bulletin 18 : Per Bech:  Measurement-based care in mental disorders (New York: Springer; 2016) Foreword and Review</a></li><li><a href="INDEX8100.HTM?id=3338" target="_self">Collated Bulletin 19 : Donald F. Klein and John Davis: Diagnosis and Drug Treatment of Mental Disorders and Thomas A. Ban: Psychopharmacology in 1969</a></li><li><a href="INDEX7B0A.HTM?id=3345" target="_self">Collated Bulletin 20 : Thomas A. Ban: Schizophrenia in the Early 1970s</a></li><li><a href="INDEXAF2B.HTM?id=3355" target="_self">Collated Bulletin 21 : Thomas A. Ban, Marcelo Cetkovich-Bakmas, Ernst Franzek and Hector Warnes: Carl Wernicke’s “elementary symptoms” and “sejunction hypothesis”</a></li><li><a href="INDEXE783.HTM?id=3374" target="_self">Collated Bulletin 22 : Martin M. Katz: Clinical Trials of Antidepressants: How Changing the Model Can Uncover New, More Effective Molecules</a></li><li><a href="INDEX4AF0.HTM?id=3393" target="_self">Collated Bulletin 23 : Joseph Knoll: From the Theory of Active Reflexes to a Neurochemical Concept of Innate and Acquired Drive</a></li><li><a href="INDEXC922.HTM?id=3401" target="_self">Collated Bulletin 24 : Ildiko Miklya: The  History of Selegiline (-) Deprenyl the First Selective Inhibitor of B-Type Monoamine Oxidase and the First Synthetic Catecholaminergic Enhancer Substance</a></li><li><a href="INDEX5549.HTM?id=3411" target="_self">Collated Bulletin 25 : Joseph Knoll: The Discovery of the Enhancer Regulation in the Mammalian Brain and the Development of the Synthetic Enhancer Substances</a></li><li><a href="INDEXBEF3.HTM?id=3421" target="_self">Collated Bulletin 26 : Profiles of clinicians and researchers who were instrumental for the birth and/or contributed to the development of neuropsychopharmacology: Julius Axelrod, Frank Ayd, Frank Berger, Hans Berger and Hermann Blaschko</a></li><li><a href="INDEXDEB4.HTM?id=3428" target="_self">Collated Bulletin 27 : Profiles of clinicians and researchers who were instrumental for the birth and/or contributed to the development of neuropsychopharmacology. Charles Bradley, Philip B. Bradley, Bernard B. Brodie, John Cade and John Delay</a></li><li><a href="INDEX65AD.HTM?id=3436" target="_self">Collated Bulletin 28 : Profiles of clinicians and researchers who were instrumental for the birth and/or contributed to the development of neuropsychopharmacology. Edmundo Fischer, W. Horsley Gantt, Turan M. Itil, Hitoshi Itoh and Paul Kielholz</a></li><li><a href="INDEX9D53.HTM?id=3446" target="_self">Collated Bulletin 29 : Profiles of clinicians and researchers who were instrumental for the birth and/or contributed to the development of neuropsychopharmacology. Nathan S. Kline, Roland Kuhn, Heinz E. Lehmann, Laszlo Meduna and Dionisio Nieto Gomez</a></li><li><a href="INDEX05ED.HTM?id=3454" target="_self">Collated Bulletin 30 : Profiles of clinicians and researchers who were instrumental for the birth and/or contributed to the development of neuropsychopharmacology. Alfred Pletscher, Juri Saarma, Sydney Spector, Leo Sternbach, Edward Trautner and Joseph Wo</a></li><li><a href="INDEX51CB.HTM?id=3464" target="_self">Collated Bulletin 31 : Thomas A. Ban: Lithium. 1. Discovery of its therapeutic effect in psychiatry. Johan Schioldann, William T. Hammond and Carl Lange</a></li><li><a href="INDEX7AE6.HTM?id=3471" target="_self">Collated Bulletin 32 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective. 2. Introduction into treatment in psychiatry. Samuel Gershon: Profiles of John Cade and Edward Trautner</a></li><li><a href="INDEX9492.HTM?id=3479" target="_self">Collated Bulletin 33 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective. 3. Early Years. Samuel Gershon: First-Hand Accounts</a></li><li><a href="INDEX5A82.HTM?id=3489" target="_self">Collated Bulletin 34 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective</a></li><li><a href="INDEXBC82.HTM?id=3497" target="_self">Collated Bulletin 35 : Thomas A. Ban: Lithium. 4. Controversy. Barry Blackwell vs Paul Grof and Jules Angst</a></li><li><a href="INDEXE7C3.HTM?id=3506" target="_self">Collated Bulletin 36 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective 5. Turning point. Paul Grof and Johan Schioldann</a></li><li><a href="INDEXF857.HTM?id=3514" target="_self">Collated Bulletin 37 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective 6. Action. Janusz Rybakowski</a></li><li><a href="INDEX6E77.HTM?id=3523" target="_self">Collated Bulletin 38 : Thomas A. Ban: 7.  Diagnosis</a></li><li><a href="INDEX680B.HTM?id=3532" target="_self">Collated Bulletin 39 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective Dedication and Preface</a></li><li><a href="INDEX516F.HTM?id=3541" target="_self">Collated Bulletin 40 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective.</a></li><li><a href="INDEX1901.HTM?id=3550" target="_self">Collated Bulletin 41 : Peter R. Martin. Volume 1. Recollections of the History of Neuropsychopharmacology Through Interviews Conducted by Thomas A. Ban</a></li><li><a href="INDEXCA36.HTM?id=3558" target="_self">Collated Bulletin 42 : Peter R. Martin. Volume 2. Recollections of the History of Neuropsychopharmacology Through Interviews Conducted by Leo E. Hollister</a></li><li><a href="INDEXE728.HTM?id=3566" target="_self">Collated Bulletin 43 : Peter R. Martin. Volume 2. Recollections of the History of Neuropsychopharmacology Through Interviews Conducted by William E. Bunney, Jr.</a></li><li><a href="INDEX0343.HTM?id=3583" target="_self">Lehmann Collection 1 : Charles E. Cahn’s interview of Heinz E. Lehmann</a><span class="hidden">.</span></li><li><a href="INDEXAF7B.HTM?id=3591" target="_self">Lehmann Collection 2 : William E. Bunney’s interview of Heinz E. Lehmann</a></li><li><a href="INDEXC461.HTM?id=3599" target="_self">Lehmann Collection 3 : Heinz Edgar Lehmann by Barry Blackwell</a></li><li><a href="INDEXC5D4.HTM?id=3607" target="_self">Lehmann Collection 4 : Heinz Lehmann and Douglas Hospital by Charles C. Cahn</a></li><li><a href="INDEXEC5F.HTM?id=3616" target="_self">Lehmann Collection 5 : Heinz Edgar Lehmann’s research profile by Antonio E. Nardi.</a></li><li><a href="INDEXDB89.HTM?id=3624" target="_self">Lehmann Collection 6 : Heinz E. Lehmann by Edward Shorter.</a></li><li><a href="INDEXB434.HTM?id=3633" target="_self">Lehmann Collection 7 : Per Bech’s comment on Heinz E. Lehmann*</a></li><li><a href="INDEX1767.HTM?id=3641" target="_self">Lehmann Collection 8 : Paul Grof’s comment on Heinz E. Lehmann. A few personal recollections</a></li><li><a href="INDEX7BD1.HTM?id=3650" target="_self">Lehmann Collection 9 : Irwin J. Kopin’s comment on Heinz E. Lehmann.</a></li><li><a href="INDEXAE03.HTM?id=3661" target="_self">Lehmann Collection 10 : Mary and Philip Seeman's comment</a></li><li><a href="INDEXDDD3.HTM?id=3680" target="_self">Lehmann Collection 11 : A Tribute to Heinz Edgar Lehmann by Hector Warnes.</a></li><li><a href="INDEX42F1.HTM?id=3689" target="_self">Lehmann Collection 12 : Heinz Edgar Lehmann:  Publication</a></li><li><a href="INDEX8FD0.HTM?id=3698" target="_self">Lehmann Collection 13 :  Thomas A. Ban: My Personal Notes on Heinz Lehmann</a></li><li><a href="INDEXC658.HTM?id=3707" target="_self">Lehmann Collection 14 : Thomas A. Ban: Heinz E. Lehmann and Psychopharmacology</a></li><li><a href="INDEXB918.HTM?id=3717" target="_self">Lehmann Collection 15 : Thomas A. Ban: Towards a clinical methodology for neuropsychological research</a></li><li><a href="INDEXF57D.HTM?id=3726" target="_self">Lehmann Collection 16 : Heinz Edgar Lehmann</a></li><li><a href="INDEX1FC5.HTM?id=3734" target="_self">Lehmann Collection 17 : Heinz E. Lehmann: What is wrong with getting old?</a></li><li><a href="INDEX1A9C.HTM?id=3743" target="_self">Lehmann Collection 18 : Heinz E. Lehmann: Dreaming about Mental Health</a></li><li><a href="INDEXDC72.HTM?id=3753" target="_self">Lehmann Collection 19: Heinz E. Lehmann: Alcoholism, aggression and androgen function. Discussion of paper by Jack Mendelson</a></li><li><a href="INDEX7FE1.HTM?id=3761" target="_self">Lehmann Collection 20: Heinz E. Lehmann: Perspectives in Psychosurgery</a></li><li><a href="INDEX6E26.HTM?id=3770" target="_self">Lehmann Collection 21 : Heinz E. Lehmann: Discussion of the paper by Prof. P. Pichot:  The Treatment of Depression</a></li><li><a href="INDEX2F04.HTM?id=3778" target="_self">Lehmann Collection 22 : Heinz E. Lehmann: Harlem Valley Revisited</a></li><li><a href="INDEX8D36_2.HTM?id=3788" target="_self">Lehmann Collection 23 : Heinz E. Lehmann: Chlorpromazine: The Story of Phenothiazine Derivatives, Their Clinical Indications, the Incidence and Management of Untoward Effects and a Proposed Rational for Its Action</a></li><li><a href="INDEXC42B.HTM?id=3796" target="_self">Lehmann Collection 24 : Heinz E. Lehmann: The Anatomy of Research Funding</a></li><li><a href="INDEX7DC1.HTM?id=3804" target="_self">Lehmann Collection 25 : Program of Academic morning in honor of Dr. Heinz Lehmann</a></li><li><a href="INDEX212A.HTM?id=3814" target="_self">Lehmann Collection 26 : Heinz E. Lehmann: Types and Characteristics of Objective Measures of Psychopathology</a></li><li><a href="INDEX40D0.HTM?id=3877" target="_self">Classification of Functional Psychoses 1 : Preface and Recommended Reading</a></li><li><a href="INDEXF49C.HTM?id=3888" target="_self">Classification of Functional Psychoses 2 : Introduction</a></li><li><a href="INDEX12CF.HTM?id=3896" target="_self">Classification of Functional Psychoses 3 : ICD-9 and DSM-III</a></li><li><a href="INDEX93EE.HTM?id=3906" target="_self">Classification of Functional Psychoses 4: Classification of Mental Disorders and Psychopharmacology – Diagnostic Criteria for Research</a></li><li><a href="INDEX0CDC.HTM?id=3914" target="_self">Classification of Functional Psychoses 5: The KDK Budapest</a></li><li><a href="INDEX6A56.HTM?id=3923" target="_self">Classification of Functional Psychoses 6: One- and Two-Dimensional Diagnoses</a></li><li><a href="INDEX44FB.HTM?id=3933" target="_self">Classification of Functional Psychoses 7: Delusional Development and Delusional Psychoses</a></li><li><a href="INDEXA244.HTM?id=3942" target="_self">Classification of Functional Psychoses 8: Bayle’s Unitary Concept of Psychosis and Endogenous Psychoses</a></li><li><a href="INDEX76A8.HTM?id=3952" target="_self">Classification of Functional Psychoses 9: Affective Psychosis</a></li><li><a href="INDEXF554.HTM?id=3960" target="_self">Classification of Functional Psychoses 10: Empirical and Pragmatic Classifications of Depression</a></li><li><a href="INDEXB28B.HTM?id=3969" target="_self">Classification of Functional Psychoses 11: Schizophrenic Psychoses</a></li><li><a href="INDEXEE78.HTM?id=3977" target="_self">Classification of Functional Psychoses 12: Cycloid Psychoses</a></li><li><a href="INDEX79BA.HTM?id=3985" target="_self">Classification of Functional Psychoses 13: Conclusions</a></li><li><a href="INDEXFDAB.HTM?id=3994" target="_self">Classification of Functional Psychoses 14: References</a></li><li><a href="INDEXF3F8.HTM?id=4011" target="_self">Delcir da Costa’s comment on collating document</a></li><li><a href="INDEXFAD4.HTM?id=4030" target="_self">Dementia Differential Diagnosis 1991 : Contents</a></li><li><a href="INDEX05BB.HTM?id=4042" target="_self">Dementia Differential Diagnosis 1991 : Conceptual Development</a></li><li><a href="INDEXA331.HTM?id=4051" target="_self">Dementia Differential Diagnosis 1991 : Dementing Illnesses</a></li><li><a href="INDEXDEF5.HTM?id=4059" target="_self">Dementia Differential Diagnosis 1991 : Modified Concept</a></li><li><a href="INDEX4686.HTM?id=4068" target="_self">Dementia Differential Diagnosis 1991 : Diagnosing of Dementing Illness</a></li><li><a href="INDEXED54.HTM?id=4077" target="_self">Dementia Differential Diagnosis 1991 : References</a></li><li><a href="INDEX0D43.HTM?id=4132" target="_self">Methodology pitfalls of clinical testing of psychopharmaceutical</a></li><li><a href="INDEX9601.HTM?id=4140" target="_self">Mental health (Psychiatry) and pharmaceuticals in a historical perspective</a></li><li><a href="INDEX114D.HTM?id=4150" target="_self">Nosology in the teaching of psychiatry. Introduction</a></li><li><a href="INDEX4294.HTM?id=4158" target="_self">Towards a clinical methodology for neuropsychopharmacological research</a></li><li><a href="INDEXD825.HTM?id=4176" target="_self">Selective Drugs Versus Heterogeneous Diagnoses. Towards a New Methodology in Psychopharmacologic Research</a></li></ul></li><li><a href="INDEXC4F2.HTM?id=2324" target="_self">Per Bech: Members of the International Committee for the Prevention and Treatment of Depression in the mid-1980s</a></li><li><a href="INDEXC2D5.HTM?id=2299" target="_self">Per Bech and Wolfgang Rutz: The Story of the International Committee for the Prevention and Treatment of Depression</a></li><li><a href="INDEX9256.HTM?id=2371" target="_self">Peter R. Martin: Historical Dictionary of Addiction</a><span class="hidden">.</span></li><li><a href="INDEX527D.HTM?id=2648" target="_self">Amara McLaughlin-Harris: The Legal History of Psychoactive Drugs</a><span class="hidden">.</span></li><li><a href="INDEXFB23.HTM?id=2184" target="_self">Carlos Morra: An Educational Model in Psychiatry</a><span class="hidden">.</span></li><li><a href="INDEX9A07.HTM?id=2428" target="_self">Carlos Morra and Ernst Franzek: Psychopathological Symptoms</a><span class="hidden">.</span></li><li><a href="INDEX0793.HTM?id=3533" target="_self">Carlos Morra and Mateo Kreiker: Psychopathology</a><span class="hidden">.</span></li></ul></li></ul></li><li><a href="INDEX4710.HTM?id=3072" target="_self">INHN Publisher</a><span class="hidden">.</span></li><li><a href="INDEX7227.HTM?id=1114" target="_self">Programs</a><span class="hidden">.</span></li><li><a href="INDEXEAE0.HTM?id=1266" target="_self">Courses</a><span class="hidden">.</span></li><li><a href="INDEX86F6.HTM?id=1296" target="_self">Interviews</a><span class="hidden">.</span></li><li><a href="INDEXEF79.HTM?id=410" target="_self">Copyright Policy</a></li><li><a href="INDEX756E.HTM?id=437" target="_self">How to cite INHN</a></li><li><a href="INDEXCF6F.HTM?id=3373" target="_self">Website Table of Contents</a></li><li><a href="INDEXD254.HTM?id=2343" target="_self">Last Uploads</a></li></ul>
					
					<div class="textBelowMenu"><!--TYPO3SEARCH_begin--><!--TYPO3SEARCH_end--></div>
				</div>
			</div>
			<div id="col2">
				<div id="col2_content" class="clearfix"><!--TYPO3SEARCH_begin--><!--TYPO3SEARCH_end--></div>
			</div>
			<div id="col3">
			  <a id="content" name="content"></a>
				<div id="col3_content" class="clearfix">
					<div class="floatbox"><!--TYPO3SEARCH_begin--><!--DMAILER_SECTION_BOUNDARY_--><div id="c4809" class="csc-default"><h1><span style="FONT-WEIGHT: normal">Thomas A. Ban<br />Neuropsychopharmacology in Historical Perspective<br />Education in the Field in the Post-Neuropsychopharmacology Era<br />Background to An Oral History of the First Fifty Years</span></h1>
<h1>Update (Volume Nine): 3a. Interviewee’s Contributions</h1>
<h1>( Bulletin 71)</h1>
<p>&nbsp;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Volume 9 Education transcripts of 19 videotaped biographic interviews. There are four MD, PhDs (Gottschalk, Klein, Pletscher and van Praag), 12 MDs (Ayd, Ban, Berger, Cole, Fink, Hollister, Itil, Janowsky, Levine, Meltzer and Sarwer-Foner) and three PhDs (Gittelman-Klein, Katz and Kornetsky) among the interviewees. The 16 MDs (including the MD, PhDs) include 13 certified psychiatrists, one microbiologist (Berger), one internist (Hollister) and one pharmacologist (Pletscher). The three PhDs are psychologists.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All interviewees are ACNP members; seven (Ayd, Cole, Fink, Gottschalk, Hollister, Kornetsky and Sarwer-Foner) are Founders; and five (Cole, Hollister, Klein, Meltzer and Simpson) are past-presidents.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All transcripts in Volume 9 are based on the second interview of interviewees and all but five interviews were conducted at ACNP’s annual meetings from 1994 to 2008.&nbsp; From the five interviews conducted between annual meetings, four (Berger, Cole, Gottschalk and Hollister) were conducted in Nashville and one (Pletscher) at CINP’s biennial congress in Paris.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The 19 interviewees were interviewed by 12 interviewers: nine interviewers (Angrist, Belmaker, Braslow, William Bunney, Carpenter, John Davis, Koslow, Leckman and Tamminga), conducted one interview; two (Healy and Tone), conducted two; and one (Ban) six. From the 12 interviewers 10 are peers of the interviewees and two are medical historians (Braslow and Tone).&nbsp; One of the medical historians (Braslow) is also a&nbsp; qualified psychiatrist. </p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; By the time Volume 9 was published six of the interviewees (Ayd, Berger, Cole, Gottschalk, Hollister and Pletscher) had passed away (Ban 2011a; Blackwell 2011).</p>
<p>&nbsp;</p>
<p><i>Contributions of Interviewees</i></p>
<p>&nbsp;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the following some contributions of interviewees in Volume 6 to the development of neuropsychopharmacology are reviewed (Ban 2011b). </p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In 1947 <i>Frank M. Berger</i> observed that mephenesin has muscle relaxant and tranquilizing effects in animal (Berger 1947). In 1949 he reported on the effect of the substance on spastic and hyperkinetic disorders (Berger and Schwartz 1948). Berger’s determination to synthesize and develop a mephenesin-like drug with a longer duration of action led, in 1955, to the introduction of meprobamate for the treatment of anxiety disorders (Berger 1954). During the 1950s and ‘60s, Berger developed several other structurally similar propanediol preparations to meprobamate, e.g., tybamate (Berger 1977).</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In 1950 <i>Conan Kornetsky</i> was a member of Harris Isbell’s team that reported experimental findings in chronic barbiturate intoxication (Isbell, Altschul, Kornetsky et al. 1950).&nbsp; In a subsequent report Kornetsky provided more details of his findings on the psychological effects of chronic barbiturate use (Kornetsky 1951). Kornetsky began with his research on the effects of anxiety and morphine on the anticipation and perception of painful radiating thermal stimuli in the early 1950s (Kornetsky 1954). During the following years he extended the scope of his studies to the pharmacology of nociception and in 2006 reported that, using thermal radiation and intra-cerebral electric stimulation, there was no difference in nociceptive threshold and analgesic response to morphine between old and young rats (Crosby, Knapp and Kornetsky 2006). In collaboration with Knapp, Tozier and Pak he also revealed that medial forebrain stimulation enhanced intracranial nociception and attenuated morphine-induced analgesia (Kornetsky, Knapp, Toazier and Pak 2010).&nbsp; </p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In 1954 <i>Turan M. Itil</i> was among the first to publish, in collaboration with Dieter Bente, on the effects of chlorpromazine (Megaphen) on the human EEG (Bente and Itil 1954a). During the 1950s he also reported on the effect of promethazine on phantom pain and on EEG changes with several psychotropic drugs, e.g., reserpine, lysergic acid diethylamide (Bente and Itil&nbsp; 1954b, 1957,&nbsp; 1967). In the 1960s Itil developed “quantitative EEG” with Max Fink and classified psychotropic drugs with the employment of the EEG (Itil, Shapiro and Fink 1968). In the 1970s he extended his research to include the detection of psychotropic properties of drugs. It was in the course of this research that he discovered the &nbsp;antidepressant properties of mianserin (Itil 1998; Itil, Polvan &nbsp;and Hsu 1972). By the 1980s Itil also employed “computerized EEG” in predicting treatment response to psychotropic drugs, e.g., response to neuroleptics in schizophrenia (Itil&nbsp; and Shapiro 1981). He continued his research with “computerized EEG” throughout the 1980s and 1990s.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In 1955 <i>Alfred Pletscher, </i>a member of Bernard Brodie’s team, in preparation for his new position with Roche, was first to demonstrate, in collaboration with Parkhurst Shore, that reserpine releases serotonin in the brain (Pletscher, Shore and Brodie 1955). In 1956 he also showed that the monoamine oxidase inhibitor, iproniazid, increased cerebral serotonin levels (Pletscher 1956). In the 1960s, as Roche’s research director, Pletscher was involved in the development of benzquinolzines, a series of reserpine-like monoamine depleting drugs with psychotropic effects (Pletscher, Brossi and Gey 1962). He was also instrumental in developing benserazide, an extracerebral decarboxylase inhibitor that enhanced the therapeutic effect of levodopa in Parkinson’s disease (Bartholini, Burcard, Pletsher and Bates 1967). By the late 1970s Pletscher was no longer involved in neuropharmacology research. </p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In 1955 <i>Leo E Hollister</i> was one of the first to report on the therapeutic effect of reserpine in the treatment of schizophrenia and of Metrazol (pentylenetetrazol) and Hydergine in nervous and mental disease associated with old age (Hollister 1955; Hollister and Fitzpatrick&nbsp; 1955; Hollister, Krieger, Kringel and Roberts 1955; Hollister, Traub and Beckman&nbsp; 1956).&nbsp; Hollister was also first to report, in 1961, on withdrawal reaction after chlordiazepoxide discontinuation (Hollister, Montzenbecker and Degan&nbsp; 1961). During the 1960s and ‘70s Hollister was involved in studying the effect of numerous psychotropic drugs. The first edition of Hollister’s monograph, <i>The Clinical Use of Psychotherapeutic Drugs,</i> was published in 1973 (Hollister 1973, 1978). As multi-center studies replaced single center clinical investigations in the 1980s, Hollister gradually withdrew from clinical investigations. </p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In 1955 <i>Gerald J Sarwer-Foner </i>was among the first in Canada to study the use of reserpine and other psychotropic drugs in an “open psychiatric setting” (Sarwer-Foner and Ogle&nbsp; 1955). In 1956 he reported that reserpine and chlorpromazine, instead of alleviating, enhanced anxiety in some patients (Sarwer-Foner and Ogle 1956). He attributed the paradoxical effect of these drugs to interference with ego defenses when “activity-passivity” mechanisms are involved (Sarwer-Foner 1957). Throughout the years Sarwer-Foner has maintained that in patients’ response to psychotropic drugs psychodynamic mechanisms play a role (Sarwer-Foner 1960, 1966).</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In 1955 <i>Frank J. Ayd, Jr</i>. published one of the first papers in the United States on the use of chlorpromazine in psychiatric patients (Ayd 1955). He became involved in clinical investigations with psychotropic drugs and in 1958 reported on the differential effect of several phenothiazines (Ayd 1959). In 1960 Ayd was among the first to report on the antidepressant effect of amitriptyline (Ayd 1960). One year later, in 1961, he published his monograph, <i>Recognizing the Depressed Patient</i> (1961a). About the same time, he also published the findings of his survey on neuroleptic-induced “extrapyramidal reactions” (Ayd 1961b). In the mid-1960s Ayd launched the <i>International Drug Therapy Newsletter</i> to speed up dissemination of research findings with psychotropic drugs. In the 1980s Ayd gradually withdrew from clinical investigations and began with the preparation of his <i>Lexicon of Psychiatry, Neurology and Neurosciences. </i>The Lexicon was first published in 1995 (Ayd 1995).</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In 1956 <i>Louis A. Gottschalk</i> reported that in normal subjects response to pipradrol was more dependent on subjects’ personality traits than on any other factor (Gottschalk, Knapp, Ross et al. 1956). Subsequently, in the 1960s, Gottschalk studied the effects of several phenothiazines and benzodiazepines with the employment of his first “content analysis scales” (Glaser, Gottschalk, Fox and Lippsert 1965; Glaser, Gottschalk and Springer 1961; Gottschalk, Glaserr and Springer 1963; Gottschalk, Glaser, Springer et al. 1960). &nbsp;During the 1970s Gottschalk became involved in pharmacokinetic research and studied the relationship between blood levels and clinical response to psychotropic drugs. It was&nbsp; in the course of these studies that he identified the metabolites of thioridazine and mesoridazine responsible for the cardiac effects of these drugs (Gottschalk and Merlis 1979). In 1980 Gottschalk reported his findings from toxicological and pathological studies on “drug-involved death” (Gottschalk and Cravey 1980). Throughout the years “content analysis of speech” remained central in Gottschalk’s research. His instrument for “content analysis of speech” was translated into several languages and was used in studies with psychotropic drugs (Gottschalk 1994). </p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In 1956 <i>Jonathan O. Cole </i>organized the first conference on <i>Problems in the Evaluation of Pharmacotherapy in Mental Illness (</i>Cole and Gerard 1959)<i>.</i> Subsequently, he was the architect of the NIMH collaborative studies on the effectiveness of phenothiazine treatment in acute schizophrenia (National Institute of Mental Health Psychopharmacology Research Branch 1967; National Institute of Mental Health Psychopharmacology Service Center 1964). In 1965 Cole co-authored a paper with Gerald Klerman on the efficacy of imipramine and some other tricyclic antidepressants in depressive illness (Klerman and Cole 1965). During the 1980s he collaborated with George Gardos on tardive dyskinesia research, and with Alan Schatzberg and Joseph Schildkraut in developing a biochemical classification of depression (Cole, Gardos and Bolig&nbsp; 1992; Gardos, Cole and LaBrie&nbsp; 1982; Schatzberg, Samson, Bloomingdale et al 1989). In 1990, with Teicher and Glod, Cole was first to report on the emergence of intense suicidal preoccupation during fluoxetine treatment (Teicher, Glod and Cole 1990). &nbsp;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In 1957<i> Max Fink</i> demonstrated the relation of Δ-activity in the human EEG and behavioral response to ECT (Fink and Kahn 1957).&nbsp; One year later, in 1958, Fink was among the first to report on the differential effect of antipsychotic, antidepressant and antianxiety drugs on the human EEG and behavior (Fink 1959). In the same year, in collaboration with Shaw, Gross and Coleman, he showed the superiority of chlorpromazine to insulin coma therapy in the treatment of psychosis (Fink, Shaw, Gross and Coleman 1958). During the 1960s and ’70s Fink’s research was focused on pharmaco-EEG, digital computer analysis of the human EEG and EEG classification of psychotropic drugs (Fink 1968, 1998; Fink, Itil and Shapiro 1967). In the 1990s his interest shifted and in 2003, he published with Allan Taylor his monograph, <i>Catatonia</i>, and in 2006, <i>Melancholia&nbsp;&nbsp; </i>(Fink and Taylor 2006; Taylor and Fink 2003).&nbsp; </p>
<p>&nbsp;</p>
<p><b>References:</b></p>
<p>&nbsp;</p>
<p>Ayd FJ. Treatment of psychiatric patients with Thorazine. South Med J 1955; 48: 177-86.</p>
<p>Ayd FJ. A clinical analysis of the differential effects of phenothiazine derivatives. In: Bradley PB, Deniker P, Radouco-Thomas C, editors. Neuropsychopharmacology. Amsterdam: Elsevier; 1959, p. 487-8.</p>
<p>Ayd FJ. Amitriptyline (Elavil) therapy of depressive reactions. Psychosomatiics 1960; 1: 320-5.</p>
<p>Ayd FJ. Recognizing the Depressed Patient. New York: Grune &amp; Stratton; 1961a.</p>
<p>Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961b; 175: 1056-60.</p>
<p>Ayd FJ. Lexicon of Psychiatry, Neurology and the Neurosciences. Philadelphia: Lippincott Williams &amp; Wilkins; 1995.</p>
<p>Bartholini G, Burkard WP, Pletscher A, Bates HM. Increase of cerebral catecholamine caused by 3,4 dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature 1967; 215: 852-3. </p>
<p>Bente D, Itil TM. Zur Wirkung des Phenothiazin Körpers Megaphen und das menschliche Hirnstrombild.&nbsp; Arzneimittel Forschung 1954a; 4: 418-23. </p>
<p>Bente D, Itil TM. Periphere Anästhesie und Schmerzgeschehen. Acta Neuroveg 1954b; 7: 258-62.</p>
<p>Bente D, Itil TM. Elektroenzephalographische Veränderungen unter extrem hochen&nbsp; Reserpinedosen. In: Garrattini S, Ghetti V, editors. Psychotropic Drugs. Amsterdam: Elsevier; 1957, pp. 286-94.</p>
<p>Bente D, Itil TM. Vergleichende klinisch electroenzephalographische Untersuchungen mit Pervitin und LSD-25. In: Garrattini S, Ghetti V, editors. Psychotropic Drugs. Amsterdam: Elsevier; 1967, pp. 284-5.</p>
<p>Berger FM. The mode of action of myanesin. Br J Pharmacol Chemotherapy 1947; 2: 241-50.</p>
<p>Berger FM. The pharmacodynamic properties of 2-methyl-2-n-1, 3 popanediol dicarbamate (Miltown), a new interneuronal blocking agent. J Pharmacol Exp Ther 1954; 112: 413-23.</p>
<p>Berger FM. Meprobamate and other glycol derivatives. In: Usdin E, Forrest IS, editors. Psychotherapeutic Drugs. Part II. Applications. New York: Dekker; 1977, pp. 1089-100.</p>
<p>Berger FM, Schwartz RP. Oral myanesin in the treatment of spastic and hyperkinetic disorders. JAMA 1948; 137: 772-3. </p>
<p>Cole JO, Gardos G, Bolig LA et al. Early dyskinesia vulnerability. Psychopharmacology 1992; 107: 503-10.</p>
<p>Cole JO, Gerard RW, editors. Psychopharmacology Problems in Evaluation. Proceeding of a Conference on the Evaluation of Pharmacotherapy of Mental Illness, sponsored by the National Institute of Mental Health and the National Academy of Sciences - National Research Council and the American Psychiatric Association.&nbsp; Washington, DC, September 18-22, 1956. Washington: National Academy of Sciences – National Research Council; 1959.</p>
<p>Crosby S, Knapp C,&nbsp; Kornetsky C. Nocicepive threshold and analgesic response to morphine in aged and young adult rats as determined by thermal radiation and intracerebral electrical stimulation.&nbsp; Phamaco Biochem and Behavior 2006; 84: 148-57.</p>
<p>Fink M. EEG and behavioral effects of psychopharmacologic agents. In: Bradley PB, Deniker P, Radouco-Thomas C, editors.&nbsp; Neuropsychopharmacology. Amsterdam: Elsevier; 1959, &nbsp;pp. 441-6.</p>
<p>Fink M. EEG classification of psychoactive compounds in man: Review and theory of behavioral associations. In: Efron DH, editor. Psychopharmacology A Review of Progress 1957-1967. Washington: US Government Printing Office; 1968, pp. 497-508. </p>
<p>Fink M. Phamaco-electroencephalography. A debate in psychopharmacology. In: Ban TA, Healy D, Shorter E, editors. The Rise of Psychopharmacology and the Story of CINP. Budapest: Animula; 1998, pp. 151-6.</p>
<p>Fink M, Itil T, Shapiro DM. Digital computer analysis of the human-EEG in psychiatric research. Comprehensive Psychiatry 1967; 8: 521-8.</p>
<p>Fink M, Kahn RL. Relation of EEG Δ-activity to behavioral response to electroshock. Arch Neurol Psychiatry 1957; 78: 517-25.</p>
<p>Fink M, Shaw R, Gross G, Coleman FS. Comparative study of chlorpromazine and insulin coma in the therapy of psychosis. JAMA 1958; 166: 1846-50.</p>
<p>Fink M, Taylor MA. Catatonia: A Clinician’s Guide to Diagnosis and Treatment. Cambridge: University Press; 2003.</p>
<p>Glaser GC, Gottschalk LA, Fox R, Lippsert R. Immediate changes in affect with chlordiazepoxide in juvenile delinquent boys. AMA Arch Gen Psychiatry 1965; 13: 291-5. </p>
<p>Glaser GC, Gottschalk LA, Springer KJ. An anxiety scale applicable to verbal samples. Arch Gen Psychiat 1961; 5: 593-605.</p>
<p>Gottschalk LA. The application of computerized measurement of the content analysis of the natural language to the assessment of the effects of psychoactive drugs. Methods and Findings in Experimental and Clinical Pharmacology 1999; 21: 133-8.&nbsp; </p>
<p>Gottschalk LA, Cravey RH. Toxicological and Pathological Studies in Drug Involved Death. Davis: Biomedical Publications; 1980.</p>
<p>Gottschalk LA, Glaser GC, Springer KJ. Three hostility scales applicable to verbal samples.&nbsp; Arch Gen Psychiat 1963; 9: 254-79.</p>
<p>Gottschalk LA, Glaser GC, Springer KJ, et al. Effects of perphenazine on verbal behavior patterns. AMA Arch Gen Psychiatry 1960; 2: 632-9.</p>
<p>Gottschalk LA, Knapp FT, Ross WD et al. Explorations in testing drugs affecting physical and mental activity. Studies with a new drug of potential value in psychiatric illness. JAMA 1956; 161: 1054-8.</p>
<p>Gottschalk LA, Merlis S, editors. Pharmacokinetics of Psychoactive Drugs. New York: Spectrum Publications; 1979.</p>
<p>Hollister LE. Combined hydrogenated alkaloids of ergot in mental and nervous disorders associated with old age. Dis Nerv Syst 1955; 16: 1-4.</p>
<p>Hollister LE. Clinical Use of Psychotherapeutic Drugs. Springfield: Charles C. Thomas; 1973.</p>
<p>Hollister LE. Psychopharmacology of Psychotropic Drugs. New York: Churchill Livingstone; 1978. </p>
<p>Hollister LE, Fitzpatrick DF. Oral Metrazol in the psychoses associated with old age. J&nbsp; Am Geront Soc1955; 3: 197-200. </p>
<p>Hollister LE, Krieger GE, Kringel A, Roberts RH. Treatment of schizophrenic reactions with reserpine. Ann NY Acad&nbsp; Sci 1955; 61: 92-100.</p>
<p>Hollister LE, Montzenbecker PP, Degan RO. Withdrawal reaction from chlordiazepoxide (Librium). Psychopharmacologia 1961; 2: 63-8.</p>
<p>Hollister LE, Traub L, Beckman WG. Psychiatric use of reserpine and chlorpromazine: results of double-blind studies. In: Kline N, editor. Psychopharmacology. Washington: American Association for Advancement of Science; 1956, p. 66-75. </p>
<p>Isbell H, Altschul S, Kornetsky C et al. Chronic barbiturate intoxication, an experimental study. Archives of Neurology and Psychiatry 1950; 64: 1-28.</p>
<p>Itil TM. First use of placebo. In: Ban TA, Healy D, Shorter E, editors. The Rise of Psychopharmacology and the Story of CINP. Animula: Budapest; 1998, pp. 157-60. </p>
<p>Itil TM, Polvan N, Hsu W. Clinical and EEG effects of GB-94, a tetracyclic&nbsp; antidepressant drug.&nbsp; EEG model in the discovery of new psychotropic drugs.&nbsp; Curr Ther Res&nbsp; 1972; 14: 395-413. </p>
<p>Itil TM, Shapiro DM, Fink M. Differentiation of psychotropic drugs: by quantitative EEG analysis. Aggressologie 1968; 9: 267-80.</p>
<p>Itil TM, Shapiro DM, Schneider SJ et al. Computerized EEG as a predictor of drug response in treatment resistant schizophrenics. J Nerv Ment Dis 1981; 169: 629-37. </p>
<p>Klerman GL, Cole JO. Clinical pharmacology of imipramine and related antidepressant compounds. Pharmacological Reviews 1965; 17: 101-41.</p>
<p>Kornetsky C. Psychological effects of chronic barbiturate intoxication. Archives of Neurology and Psychiatry 1951; 65: 557-67</p>
<p>Kornetsky C. The effects of anxiety and morphine on the anticipation and perception of painful radiant thermal stimuli. Journal of Comparative and Physiological Psychology 1954; 47: 130-2.</p>
<p>Kornetsky C, Knapp C, Tozier M, Pak A. Medial forebrain stimulation enhances intracranial nociception and attenuates morphine analgesia suggesting the existence of an&nbsp; endogenous opioid&nbsp; antagonist. Pharmacology, Biochemistry, Behavior 2010; 95: 273-7.</p>
<p>National Institute of Mental Health Psychopharmacology Research Branch Collaborative Study Group. Differences in clinical effects of three phenothiazines in&nbsp; “acute” schizophrenia. Dis Nerv Syst 1967; 28: 369-83.</p>
<p>National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Phenothiazine treatment of acute schizophrenia: Effectiveness. Arch Gen Psychiatry 1964; 10: 244-61. </p>
<p>Pletscher A. Beeinflussung des 5-Hydroxytryptamine stoffwechsels im Gehirn durch Isonicotinesäurehydrazide. Experientia 1956; 195; 12: 479-80.</p>
<p>Pletscher A, Brossi A, Gey KF. Benzoquinolizine derivatives: a new class of monoamine decreasing drugs with psychotropic action.&nbsp; Internat Rev Neurobiol 1962; 4.&nbsp; 275-306.</p>
<p>Pletscher A, Shore PA, Brodie BB. Serotonin release as a possible mechanism of serotonin action. Science 1955; 122: 374-5.</p>
<p>Sarwer-Foner GJ. Psychoanalytic theories of activity-passivity constructs and of the continuum of ego defenses. Experimental verification of using reserpine and chlorpromazine. AMA Arch Neurol Psychiatry 1957; 78: 413-8.</p>
<p>Sarwer-Foner GJ, editor. The Dynamics of Psychotropic Drugs. Springfield: Charles C. Thomas; 1960.</p>
<p>Sarwer-Foner GJ. Research Conference on the Depressive Group of Illnesses. Ottawa: Runge Press; 1966. </p>
<p>Sarwer-Foner GJ, Ogle W. The use of reserpine in an open psychiatric setting. Can med Assoc J 1955; 73: 187-91.</p>
<p>Sarwer-Foner GJ, Ogle W. Psychosis and enhanced anxiety produced by reserpine and chlorpromazine. Can med Assoc J 1956; 75: 526-32.</p>
<p>Schatzberg AF, Samson A, Bloomingdale KL, Orsulak PJ, Gershon B, Kizuka PP, Cole JO, Schildkraut J. Towards a biochemical classification of depressive disorders. X Urinary catecholamines, their metabolites and D-type scores&nbsp; in subgroups of depressive disorders. Arch Gen Psychiatry 1989; 46: 260-8.&nbsp; </p>
<p>Taylor MA, Fink M. Melancholia: The Diagnosis, Pathophysiology and Treatment of Depression. Cambridge: Cambridge University Press; 2006. </p>
<p>Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment.&nbsp; Am J Psychiatry 1990; 147: 207-10.</p>
<p>&nbsp;</p>
<p>May 30, 2019</p></div><!--DMAILER_SECTION_BOUNDARY_END--><!--TYPO3SEARCH_end--></div>
				</div>
				<div id="ie_clearing">&nbsp;</div>
			</div>
		</div>
		<div id="footer">&copy; INHN 2012-2022 ::: INHN Central Office  · Av. Sagrada Familia Esq Nazaret · Córdoba, Córdoba X5000 · Argentina  ::: email: inhn@inhn.org</div>
	</div>
</div>





<script src="IMAGES/URCHIN.JS" type="text/javascript">
</script>
<script type="text/javascript">
_uacct = "UA-39727086-1";
urchinTracker();
</script>
</body>
</html>